Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35653481.
- Also identified by DOI 10.1126/science.abn0611 and PMC identifier 7613620.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aminoacyl transfer RNA (tRNA) synthetases (aaRSs) are attractive drug targets, and we present class I and II aaRSs as previously unrecognized targets for adenosine 5'-monophosphate-mimicking nucleoside sulfamates. The target enzyme catalyzes the formation of an inhibitory amino acid-sulfamate conjugate through a reaction-hijacking mechanism. We identified adenosine 5'-sulfamate as a broad-specificity compound that hijacks a range of aaRSs and ML901 as a specific reagent a specific reagent that hijacks a single aaRS in the malaria parasite <i>Plasmodium falciparum</i>, namely tyrosine RS (<i>Pf</i>YRS). ML901 exerts whole-life-cycle-killing activity with low nanomolar potency and single-dose efficacy in a mouse model of malaria. X-ray crystallographic studies of plasmodium and human YRSs reveal differential flexibility of a loop over the catalytic site that underpins differential susceptibility to reaction hijacking by ML901.
Medical subject headings
- Antimalarials
- Malaria, Falciparum
- Molecular Targeted Therapy
- Plasmodium falciparum
- Protein Biosynthesis
- Protozoan Proteins
- Tyrosine-tRNA Ligase